Comprehensive Monograph: Isoniazid (DB00951)

Executive Summary

Isoniazid (INH) stands as a paradigm of 20th-century pharmaceutical achievement, a "wonder drug" that fundamentally altered the trajectory of tuberculosis (TB), a global pandemic that had plagued humanity for millennia. Its introduction in 1952 transformed a chronic, often fatal disease into a curable condition, marking the dawn of modern, effective chemotherapy for TB. However, the legacy of isoniazid is now characterized by a profound duality. Its continued indispensability as a first-line agent is perpetually challenged by a significant toxicity profile, which is intricately linked to patient pharmacogenetics, and by the escalating global crisis of antimicrobial resistance. This monograph provides an exhaustive analysis of isoniazid, synthesizing its history, physicochemical properties, complex pharmacology, clinical applications, and the contemporary challenges that define its use.

The primary findings of this report underscore isoniazid's complex nature. It remains a cornerstone of therapy for both active and latent TB, valued for its potent bactericidal activity against susceptible strains of Mycobacterium tuberculosis.[1] Its mechanism of action is elegant in its specificity: it is a prodrug that requires activation by the mycobacterial KatG enzyme to form an active adduct that inhibits the synthesis of mycolic acids, components essential and unique to the bacterial cell wall.[2] This specificity, however, also represents a vulnerability, as mutations in the activating enzyme confer high-level resistance.

The metabolism of isoniazid is a critical determinant of its clinical utility and risk. The primary metabolic pathway, N-acetylation via the N-acetyltransferase 2 (NAT2) enzyme, is subject to genetic polymorphism, creating distinct "slow" and "fast" acetylator phenotypes within the human population.[1] This genetic variability is a crucial factor influencing both therapeutic efficacy and the risk of severe adverse events, most notably dose-dependent hepatotoxicity and peripheral neuropathy.[6] The rise of isoniazid-resistant TB, frequently a harbinger of multidrug-resistant TB (MDR-TB), now poses a formidable threat to global TB control efforts, driven primarily by mutations in the bacterial genes

katG and inhA.[2] Consequently, the future of TB therapy is shifting toward strategies that embrace personalized medicine, such as genotype-guided dosing of isoniazid, and the development of novel, shorter-course combination regimens designed to overcome resistance and improve patient outcomes.[8]

Drug Identification and Physicochemical Properties

A precise understanding of the chemical and physical characteristics of a therapeutic agent is fundamental to its application in pharmacology, formulation science, and clinical practice. This section provides the definitive identification and property data for isoniazid.

Nomenclature and Identifiers

Isoniazid is known by several names and is cataloged in numerous international chemical and pharmacological databases.

• Generic Name: Isoniazid [1]
• Systematic (IUPAC) Name: Pyridine-4-carbohydrazide [2]
• Common Synonyms & Acronyms: Isonicotinic acid hydrazide, INH, INAH, Isonicotinohydrazide, Isonicotinic hydrazide [2]
• Brand Names: Nydrazid, Rimifon, Laniazid, Isonarif, Isotamine, Isotamine B, Rifamate, Rifater [1]
• Key Registry Numbers:
• CAS Number: 54-85-3 [2]
• DrugBank ID: DB00951 [1]
• PubChem CID: 3767 [2]
• ATC Code: J04AC01 (Isoniazid), J04AC51 (Isoniazid, combinations) [11]
• FDA UNII: V83O1VOZ8L [2]

Chemical and Physical Data

The physicochemical properties of isoniazid dictate its behavior in both pharmaceutical formulations and biological systems. It is a small molecule drug characterized as an odorless, colorless or white crystalline powder.[11] Its taste is described as slightly sweet initially, followed by a bitter aftertaste.[11] Key properties are summarized in Table 1.

Table 1: Physicochemical Properties of Isoniazid

Property	Value	Source(s)
IUPAC Name	Pyridine-4-carbohydrazide	2
Common Synonyms	Isonicotinic acid hydrazide, INH, INAH	2
CAS Number	54-85-3	2
DrugBank ID	DB00951	1
Molecular Formula	C6​H7​N3​O	2
Molar Mass	137.14 g/mol	2
Appearance	Odorless, colorless or white crystals/crystalline powder	11
Melting Point	171-173 °C	11
Water Solubility	14 g/100 mL (at 25 °C); 125 g/L	11
Stability Notes	Stable, but may be sensitive to air and light. Combustible.	11
Key Incompatibilities	Strong oxidizing agents, chloral, aldehydes, iodine, ferric salts, hypochlorites, sugars, ketones.	11

The fundamental physicochemical properties of isoniazid, particularly its high water solubility and simple, small molecular structure, are directly responsible for its favorable clinical profile and decades-long success. The compound's notable solubility in water, reported as 14 g per 100 mL at 25 °C, allows for the effective formulation of oral dosage forms, including tablets and syrups, which facilitates rapid and complete absorption from the gastrointestinal tract.[5] Concurrently, its small molecular size, with a molar mass of approximately 137 g/mol, and hydrophilic character enable efficient passive diffusion across biological membranes.[2] This results in extensive distribution throughout all body tissues and fluids, including anatomically privileged sites such as the cerebrospinal fluid and the caseous, necrotic centers of tuberculous granulomas.[5] Therefore, these basic chemical and physical attributes are not merely descriptive data points; they form the essential physical basis for isoniazid's excellent bioavailability and its capacity to achieve therapeutic concentrations at the site of infection, which are prerequisites for its potent antimycobacterial activity.

Historical Context: The Discovery and Impact of a "Wonder Drug"

The story of isoniazid is a remarkable narrative of serendipity, systematic science, and profound public health transformation. Its discovery and deployment effectively ended an era of medical despair and ushered in the modern age of tuberculosis chemotherapy.

Pre-Antibiotic Era

Before the mid-20th century, a diagnosis of tuberculosis, or "consumption," was often a death sentence. The disease reached epidemic proportions in the urbanized societies of Europe and North America during the 18th and 19th centuries, becoming a leading cause of mortality.[19] In the absence of effective antimicrobial agents, treatment was palliative and largely ineffective. The cornerstone of care was the sanatorium movement, which began in the mid-1800s with pioneers like Hermann Brehmer.[19] Patients were isolated and prescribed a regimen of strict rest, nutritious food, and, most importantly, fresh air.[22] When this failed, physicians resorted to invasive and often disfiguring surgical procedures known as collapse therapy, such as artificial pneumothorax or thoracoplasty, in a desperate attempt to rest the diseased lung.[21] While public health measures and improved hygiene led to a slow decline in mortality from the early 20th century, the disease remained a fearsome and intractable foe.[20]

The Serendipitous Discovery

Isoniazid was first synthesized in 1912 by two PhD candidates, Hans Meyer and Josef Mally, at the German Charles University in Prague.[2] Their work was a purely academic exercise in organic chemistry, and they were entirely unaware of their compound's immense biological potential. For four decades, the molecule remained a chemical curiosity, forgotten on laboratory shelves.[2]

The impetus for its rediscovery came from the intense post-World War II search for effective antitubercular drugs. The first major breakthrough was the discovery of streptomycin by Selman Waksman in 1944, followed shortly by para-aminosalicylic acid (PAS) in 1945.[19] While these drugs offered the first real hope, their use was constrained by significant toxicity and the rapid emergence of bacterial resistance when used as monotherapy.[19] This spurred a concerted effort to find better agents. Researchers at several pharmaceutical companies, including Bayer in West Germany, and Hoffmann-La Roche and E.R. Squibb & Sons in the United States, began investigating compounds related to nicotinamide and a class of drugs known as thiosemicarbazones, which had shown modest anti-TB activity.[23] In a remarkable coincidence, between 1951 and 1952, these three companies independently and almost simultaneously synthesized or re-evaluated isoniazid and discovered its extraordinary and highly specific potency against

M. tuberculosis.[2]

The Dawn of Modern TB Therapy

The formal announcement of isoniazid's efficacy in 1952 was a watershed moment in the history of medicine, met with widespread media attention and hailed as the arrival of a "wonder drug".[19] Clinical trials, including those led by Walsh McDermott and Carl Muschenheim, rapidly confirmed its superiority over all existing agents.[2] Isoniazid was found to be remarkably inexpensive to produce, generally well-tolerated in initial studies, and powerfully effective, even against mycobacterial strains that were already resistant to streptomycin and PAS.[19]

Its introduction led to the development of "triple therapy"—a combination of isoniazid, streptomycin, and PAS—which achieved cure rates between 90% and 95%.[23] This unprecedented success rendered the sanatoriums and the practice of collapse therapy obsolete virtually overnight.[20] The discovery of isoniazid marked the definitive start of the modern era of effective, short-course chemotherapy for tuberculosis and established a treatment paradigm that has remained a cornerstone of global public health for over 70 years.[19]

The history of isoniazid offers a powerful case study in the nature of scientific progress. Its journey from an obscure chemical synthesized in 1912 to a world-changing medicine 40 years later highlights the critical role of serendipity in discovery.[2] Its potential was realized not through targeted design but as an accidental finding during the investigation of less effective related compounds.[24] However, chance alone was insufficient. The translation of this discovery into a reliable therapeutic tool required systematic, rational, and cooperative clinical evaluation by researchers who rigorously established its efficacy, safety profile, and role in combination therapy to combat resistance.[2] This journey also illustrates the cyclical nature of pharmaceutical development. The initial euphoria surrounding this "wonder drug" has been tempered over the subsequent decades by the clinical realities of its significant hepatotoxicity and the global emergence of widespread drug resistance.[1] The agent that solved the crisis of incurable TB in the 1950s has, in turn, created new and formidable clinical challenges—drug-induced liver injury and multidrug-resistant TB—that drive the contemporary search for its replacements and for optimized, safer treatment regimens.[10] This trajectory demonstrates that therapeutic breakthroughs are rarely final solutions but are often pivotal steps in an ongoing cycle of discovery, challenge, and innovation.

Comprehensive Pharmacological Profile

The clinical utility of isoniazid is dictated by its unique interactions with both the target pathogen, Mycobacterium tuberculosis, and the human host. A granular analysis of its mechanism of action, pharmacokinetics, and the pharmacogenetics of its metabolism is essential for its safe and effective use.

A. Mechanism of Action and Pharmacodynamics

Isoniazid's potent and specific antimycobacterial effect is the result of a multi-step process that begins with its activation within the bacterial cell.

Prodrug Activation

Isoniazid is a prodrug, a compound that is pharmacologically inert until it is metabolically converted into its active form.[1] This activation step is the key to its selective toxicity. The conversion is catalyzed by a mycobacterial enzyme, catalase-peroxidase, which is encoded by the

katG gene.[1] This enzyme, which is not present in human cells, performs a one-electron oxidation of isoniazid, initiating a cascade that generates several highly reactive species, most importantly the isonicotinic acyl radical.[2] Recent research also suggests that host enzymes, such as myeloperoxidase (MPO) found in neutrophils, may contribute to this activation process, particularly within the inflammatory environment of a granuloma.[33]

Primary Target: Mycolic Acid Synthesis

The central mechanism of isoniazid's bactericidal action is the inhibition of mycolic acid synthesis, a pathway vital for the integrity of the mycobacterial cell wall.[1]

1. Formation of the Active Adduct: The isonicotinic acyl radical, generated by KatG, spontaneously and covalently couples with the essential cellular cofactor nicotinamide adenine dinucleotide (NAD+) to form a nicotinoyl-NAD adduct (INH-NAD).[2]
2. Inhibition of InhA: This INH-NAD adduct is the primary active molecule. It functions as a potent, slow, tight-binding competitive inhibitor of a key mycobacterial enzyme, the NADH-dependent enoyl-[acyl-carrier-protein] reductase, commonly known as InhA.[1]
3. Disruption of the Cell Wall: InhA is an indispensable enzyme in the type II fatty acid synthase (FAS-II) system, which is responsible for the elongation of fatty acid precursors into the very-long-chain mycolic acids.[3] These unique, waxy, α-branched fatty acids are the defining structural component of the mycobacterial cell envelope. They provide a robust hydrophobic barrier that confers resistance to many common antibiotics, chemical insults, and host immune defenses.[3]
4. Bacterial Lysis: By potently inhibiting InhA, isoniazid halts the synthesis of mycolic acids. This leads to a structurally compromised and permeable cell wall, the loss of the bacterium's characteristic acid-fast staining property, and ultimately, cell lysis and death.[4] Early studies demonstrated that exposure to isoniazid causes mycobacteria to lose their ability to synthesize mycolates, an effect that precedes and correlates with the loss of cell viability.[36]

Secondary and Ancillary Mechanisms

While the inhibition of mycolic acid synthesis is the primary mechanism, evidence suggests that other actions contribute to isoniazid's overall potency. The peroxidative activation by KatG generates a range of other radical species, including nitric oxide (NO), which possess their own independent antimycobacterial and metabolic inhibitory effects.[2] Furthermore, some studies indicate that isoniazid exposure leads to a rapid inhibition of DNA synthesis, followed by inhibition of RNA and protein synthesis, suggesting a broader disruption of cellular processes.[34] It has also been shown to cause depletion of the cellular

NAD+ pool, further crippling the bacterium's metabolic capacity.[24]

Pharmacodynamic Properties

Isoniazid's activity is dependent on the metabolic state of the bacteria. It exhibits potent, time-dependent bactericidal activity against rapidly replicating mycobacteria, as this is when cell wall synthesis is most active.[1] Conversely, it is only bacteriostatic (inhibiting growth) against slow-growing or dormant mycobacteria, such as those found within the anaerobic core of caseous granulomas.[1] This dual activity is clinically significant, as successful TB therapy requires the eradication of both active and persistent bacterial populations.

The specificity of isoniazid's activation mechanism—requiring the mycobacterial KatG enzyme—is the biochemical foundation for both its remarkable selective toxicity and its narrow spectrum of activity. Because the drug is activated primarily inside the target pathogen, it has minimal effect on human cells or the vast majority of other bacteria, which is a significant therapeutic advantage that reduces off-target effects like disruption of the host microbiome.[1] This same specificity, however, is its Achilles' heel. The reliance on a single primary activating enzyme creates a simple and direct pathway for the evolution of resistance. A single point mutation in the

katG gene can prevent or severely impair the activation of the prodrug, rendering isoniazid completely ineffective and resulting in high-level clinical resistance.[2] This makes the drug highly vulnerable to the development of resistance, a major clinical liability that has shaped the course of the modern TB epidemic.

B. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The movement and modification of isoniazid within the human body are critical factors that influence its efficacy and toxicity.

• Absorption: Following oral or intramuscular (IM) administration, isoniazid is absorbed rapidly and completely, with peak plasma concentrations (Cmax​) typically achieved within 1 to 2 hours.[5] Absorption occurs primarily in the small intestine.[5] A crucial clinical consideration is the significant reduction in absorption and bioavailability when isoniazid is administered with food, particularly meals high in sugar.[1] This occurs because the hydrazide moiety of isoniazid can react with sugars to form hydrazone condensation products, which are not readily absorbed.[16] Therefore, administration on an empty stomach is recommended.
• Distribution: Isoniazid is characterized by its wide distribution throughout the body. It has a very low degree of plasma protein binding (0-15%), allowing the free drug to readily partition into all tissues and body fluids.[1] The apparent volume of distribution is approximately 0.6 L/kg.[40] This extensive distribution is clinically vital, as it enables isoniazid to penetrate effectively into sites of infection that are often difficult for other drugs to reach, including the cerebrospinal fluid (making it effective for TB meningitis) and the caseous material within tuberculous granulomas.[5]
• Metabolism: Isoniazid is extensively metabolized, primarily in the liver and intestines.[1] The principal metabolic pathway involves the acetylation of its hydrazine group by the enzyme arylamine N-acetyltransferase 2 (NAT2) to form the inactive metabolite N-acetylisoniazid (AcINH).[1] AcINH is then further hydrolyzed by an amidase to isonicotinic acid (INA) and monoacetylhydrazine (AcHz).[1] It is this monoacetylhydrazine metabolite that is directly implicated in isoniazid-induced hepatotoxicity. AcHz can be further oxidized by the cytochrome P450 enzyme CYP2E1 to form a highly reactive, electrophilic intermediate that can covalently bind to liver macromolecules, inducing oxidative stress and leading to hepatocellular necrosis.[1]
• Excretion: The elimination of isoniazid and its metabolites is primarily renal. Approximately 75-95% of an administered dose is excreted in the urine within 24 hours, predominantly as the metabolites AcINH and INA.[1] Only a small fraction of the parent drug is excreted unchanged. Minor amounts are also eliminated in feces and saliva.[5]

C. The Clinical Significance of Acetylator Phenotypes

The pharmacogenetics of isoniazid metabolism represent one of the earliest and most well-characterized examples of how genetic variation can dictate drug response and toxicity.

• Genetic Basis: The rate at which an individual metabolizes isoniazid is a stable, genetically determined trait governed by polymorphisms in the NAT2 gene.[1] The presence of different NAT2 alleles results in a trimodal distribution of metabolic capacity within the population, categorizing individuals into three main phenotypes:
• Slow Acetylators: These individuals are homozygous for two recessive, low-activity NAT2 alleles. They metabolize isoniazid slowly.[6]
• Intermediate Acetylators: These individuals are heterozygous, carrying one high-activity ("rapid") allele and one low-activity ("slow") allele.[6]
• Fast (or Rapid) Acetylators: These individuals are homozygous for two dominant, high-activity NAT2 alleles (e.g., NAT2*4) and metabolize the drug quickly.[6]
• Pharmacokinetic Consequences: This genetic variation has a profound impact on drug exposure. The elimination half-life (t1/2​) of isoniazid differs dramatically between phenotypes, ranging from 2 to 5 hours in slow acetylators to as short as 0.5 to 1.6 hours in fast acetylators.[1] Consequently, for a given standard dose, slow acetylators experience significantly higher peak plasma concentrations and a larger area under the concentration-time curve (AUC), indicating greater overall drug exposure, whereas fast acetylators clear the drug much more rapidly, leading to lower systemic exposure.[6]
• Clinical Implications for Efficacy: While most studies have found that slow and fast acetylators respond equally well to standard daily multidrug TB regimens, the difference in drug exposure can be clinically meaningful in certain scenarios.[6] In intermittent dosing schedules (e.g., once or twice weekly), the lower drug exposure in fast acetylators may fall below the therapeutic threshold, increasing the risk of treatment failure, relapse, or the selection of drug-resistant mutants.[6]
• Clinical Implications for Toxicity: The link between acetylator status and toxicity is profound.
• Peripheral Neuropathy: Slow acetylators are at a significantly higher risk of developing this dose-dependent side effect. Their prolonged exposure to higher concentrations of the parent drug, isoniazid, leads to greater interference with pyridoxine (vitamin B6) metabolism, precipitating the neuropathy.[6]
• Hepatotoxicity: The relationship is complex, but the weight of evidence suggests that slow acetylators are also at a greater risk of developing isoniazid-induced liver injury.[6] Although fast acetylators theoretically produce the toxic acetylhydrazine metabolite more rapidly, it is hypothesized that in slow acetylators, the primary N-acetylation pathway becomes saturated due to the high, sustained levels of the parent drug. This saturation shunts a greater proportion of isoniazid's hydrazone metabolites down the alternative, toxifying pathway mediated by CYP2E1, leading to an overall greater production of the reactive hepatotoxins that cause liver damage.[5]

The pharmacogenetics of isoniazid metabolism create an inherent therapeutic dilemma. The standard, fixed-dose regimens recommended by global health authorities are likely suboptimal for a significant portion of the patient population. A dose that is considered safe and effective for a fast acetylator may be toxic for a slow acetylator, who experiences much higher drug exposure. Conversely, a dose that is safe for a slow acetylator may be sub-therapeutic for a fast acetylator, risking treatment failure and the development of resistance. This "one-size-fits-all" approach is a clinical compromise. It strongly suggests that the current standard of care could be substantially improved through the implementation of personalized, genotype-guided dosing strategies. Such an approach, which remains largely investigational, represents a key frontier in optimizing TB therapy to maximize efficacy while minimizing harm.[6]

Clinical Applications and Therapeutic Guidelines

The translation of isoniazid's pharmacological properties into clinical practice is governed by established therapeutic guidelines for the treatment and prevention of tuberculosis.

A. Indications and Spectrum of Antimycobacterial Activity

Isoniazid is a cornerstone agent in the global fight against tuberculosis, with clearly defined indications and a highly specific spectrum of activity.

• Primary Indication: The principal use of isoniazid is for the treatment of all forms of active tuberculosis, both pulmonary and extrapulmonary, caused by susceptible strains of M. tuberculosis.[1] It is classified as a first-line antitubercular agent and is almost always used as part of a multi-drug combination regimen to enhance efficacy and prevent the emergence of resistance.[1]
• Prophylaxis (Latent TB Infection - LTBI): Isoniazid is a key drug for the treatment of latent TB infection, a prophylactic strategy aimed at preventing the progression of dormant infection to active disease.[2] For decades, isoniazid monotherapy was the standard of care for LTBI, although shorter, rifamycin-based regimens are now often preferred.[47]
• Spectrum of Activity: Isoniazid's action is highly specific to the genus Mycobacterium. It is potently active against members of the M. tuberculosis complex, which includes M. tuberculosis, M. bovis, and M. africanum, as well as against M. kansasii.[1] It is also used off-label in combination regimens for some nontuberculous mycobacterial (NTM) infections, such as those caused by the M. avium complex (MAC), where it is not bactericidal but appears to potentiate the activity of other drugs like rifampin.[2] Notably, isoniazid lacks activity against M. leprae, the causative agent of leprosy, which is thought to be due to an inactivated katG gene in that species.[3]

B. Dosing and Administration Regimens

The administration of isoniazid is guided by detailed, evidence-based regimens that vary by indication, patient age, and treatment phase.

• Formulations: Isoniazid is available in several formulations to accommodate different clinical needs: oral tablets (commonly 100 mg and 300 mg), a pediatric oral syrup (50 mg/5 mL), and an injectable solution (100 mg/mL) for intramuscular (IM) administration when the oral route is not feasible.[5]
• Administration: To ensure optimal bioavailability, oral isoniazid should be administered on an empty stomach, at least 30 minutes before or 2 hours after a meal.[41]
• Directly Observed Therapy (DOT): Adherence is critical for treatment success and preventing resistance. Therefore, all intermittent dosing regimens (e.g., twice or thrice weekly) must be administered under Directly Observed Therapy (DOT), where a healthcare worker observes the patient ingesting the medication.[2]

The standard dosing regimens for active and latent TB are summarized in Table 2.

Table 2: Standard Dosing Regimens for Isoniazid in Tuberculosis

Regimen / Indication	Patient Population	Dosage	Frequency & Duration	Max Dose	Key Comments	Source(s)
Active TB	Adults & Adolescents (≥15 yrs or >40 kg)	5 mg/kg	Daily for initial & continuation phases (typically 6 months total)	300 mg/day	Part of a 4-drug initial regimen (with RIF, PZA, EMB).	47
		15 mg/kg	Twice or thrice weekly for intermittent therapy	900 mg/dose	Must be given via DOT.	47
Active TB	Infants & Children (<15 yrs or ≤40 kg)	10-15 mg/kg	Daily for initial & continuation phases	300 mg/day	Part of a multi-drug regimen.	47
		20-40 mg/kg	Twice or thrice weekly for intermittent therapy	900 mg/dose	Must be given via DOT.	48
Latent TB (LTBI)	Adults & Adolescents (≥12 yrs)	5 mg/kg (or 300 mg)	Daily for 6 or 9 months	300 mg/day	9-month regimen is a classic standard.	5
		15 mg/kg (with Rifapentine)	Once weekly for 3 months (12 doses)	900 mg/dose	A preferred shorter-course regimen.	47
Latent TB (LTBI)	Infants & Children	10-20 mg/kg	Daily for 9 months	300 mg/day	Preferred regimen for children. Pyridoxine supplementation is essential.	48

Abbreviations: RIF=Rifampin, PZA=Pyrazinamide, EMB=Ethambutol, DOT=Directly Observed Therapy.

C. Use in Special Populations

The use of isoniazid requires careful consideration and potential modification in specific patient populations.

• Hepatic Impairment: Isoniazid should be used with extreme caution in patients with chronic liver disease.[5] It is strictly contraindicated in patients with acute liver disease of any etiology or those with a history of isoniazid-induced hepatitis.[44] While specific dose adjustments are not formally established, frequent and vigilant monitoring of liver function is mandatory in any patient with underlying liver conditions.[5]
• Renal Impairment: Isoniazid is primarily cleared via hepatic metabolism, so dosage adjustments are generally not necessary in patients with mild to moderate renal impairment.[44] However, in patients with severe renal dysfunction (e.g., creatinine clearance <10 mL/min) or those on hemodialysis, caution is advised, particularly for individuals known or suspected to be slow acetylators, as metabolites can accumulate.[44]
• Pregnancy and Lactation: For women with active TB, treatment with isoniazid during pregnancy is recommended and considered safe.[2] For latent TB, prophylactic therapy is often delayed until after delivery.[2] Isoniazid is excreted into breast milk, but in low concentrations that are considered non-toxic to the infant.[2] To mitigate the risk of neurotoxicity, concurrent supplementation with pyridoxine (vitamin B6) is mandatory for both pregnant and breastfeeding women taking isoniazid, as well as for their infants.[2]
• HIV Co-infection: Isoniazid remains a critical component of TB treatment regimens for people living with HIV. To ensure maximal efficacy in this immunocompromised population, daily dosing regimens are strongly preferred over intermittent schedules.[47] Careful management of potential drug-drug interactions with antiretroviral therapies is also essential.

Safety Profile, Adverse Effects, and Toxicity

While highly effective, isoniazid is associated with a range of adverse effects, some of which can be severe or life-threatening. A thorough understanding of its safety profile is paramount for clinical management.

A. Hepatotoxicity (Boxed Warning)

The most significant and feared adverse effect of isoniazid is drug-induced liver injury (DILI).

• Incidence and Severity: Isoniazid carries a U.S. Food and Drug Administration (FDA) boxed warning for severe and sometimes fatal hepatitis, which can develop at any time during treatment, even after many months.[44] A transient and asymptomatic elevation in serum aminotransferase levels (e.g., AST, ALT) is relatively common, occurring in 10-20% of patients, usually within the first three months of therapy.[1] In most cases, this is self-limiting. However, clinically significant hepatitis develops in approximately 1% of patients, with a fatality rate that can be as high as 4.6% among those who develop hepatitis.[7] The risk of hepatotoxicity increases significantly with age, especially in patients over 50, and is exacerbated by daily alcohol consumption and the concurrent use of other hepatotoxic drugs, particularly rifampin and pyrazinamide.[7]
• Mechanism: The mechanism of hepatotoxicity is directly linked to the metabolic pathway of isoniazid. It is not the parent drug but a reactive metabolite that causes the damage. The metabolite monoacetylhydrazine (AcHz) is oxidized by the hepatic enzyme CYP2E1 into a highly reactive, toxic intermediate.[1] This intermediate can covalently bind to hepatocytes, deplete glutathione stores, and induce severe oxidative stress, leading to hepatocellular necrosis.[5]
• Clinical Presentation: The onset of symptoms is often insidious and can mimic viral hepatitis. Patients should be counseled to immediately report symptoms such as unexplained fatigue, weakness, malaise, anorexia, nausea, vomiting, abdominal pain (especially in the right upper quadrant), dark urine, or jaundice.[7]
• Monitoring and Management: Vigilant monitoring is crucial. Baseline liver function tests (LFTs) are recommended for all patients, with periodic monitoring advised for high-risk individuals (e.g., age >35-50, alcohol users, pre-existing liver disease).[30] The medication should be promptly discontinued if a patient develops clinical symptoms of hepatitis or if LFTs rise to more than three times the upper limit of normal in the presence of symptoms, or more than five times the upper limit of normal in an asymptomatic patient.[7]

B. Neurotoxicity

Neurotoxicity is another major class of adverse effects associated with isoniazid, affecting both the peripheral and central nervous systems.

• Peripheral Neuropathy: This is the most common neurological side effect and is directly related to the dose and duration of therapy.[1] It classically presents as a symmetrical sensory neuropathy with symptoms of paresthesia—numbness, tingling, burning pain, or pins-and-needles sensations—typically starting in the hands and feet in a "stocking-glove" distribution and progressing proximally.[1]
• Mechanism: The neurotoxicity of isoniazid is not caused by a metabolite but by the parent drug itself. Isoniazid is structurally similar to pyridoxine (vitamin B6) and interferes with its metabolism. It forms a hydrazone complex with pyridoxal, effectively inactivating it and leading to a functional deficiency of the active coenzyme form, pyridoxal-5'-phosphate (PLP).[1] PLP is an essential cofactor for numerous enzymatic reactions in the body, including the synthesis of key neurotransmitters like gamma-aminobutyric acid (GABA).[55]
• Risk Factors: The risk of developing peripheral neuropathy is significantly increased in patients with predisposing conditions such as malnutrition, chronic alcoholism, diabetes mellitus, uremia (renal failure), and HIV infection.[7] Slow acetylators are also at higher risk due to prolonged exposure to the drug.[7]
• Prevention and Management: A key aspect of isoniazid therapy is that this common neurotoxicity is largely preventable. Prophylactic co-administration of pyridoxine at a dose of 10-50 mg per day is recommended for all patients, and is considered mandatory for those with identified risk factors. This simple supplementation can effectively prevent the development of neuropathy or reverse it if it occurs.[4]
• Central Nervous System (CNS) Effects: Although less common, isoniazid can cause serious CNS toxicity. Acute overdose is classically characterized by a triad of repetitive seizures that are refractory to standard anticonvulsants, metabolic acidosis, and coma.[7] In therapeutic use, rarer CNS effects can include psychosis, agitation, mood swings, memory impairment, ataxia, and optic neuritis (inflammation of the optic nerve leading to vision changes).[7] Neuroimaging with MRI in cases of INH toxicity may reveal characteristic bilateral, symmetric hyperintensities in the cerebellar dentate nuclei.[55]

The two principal toxicities of isoniazid—hepatotoxicity and neurotoxicity—arise from two fundamentally distinct and unrelated biochemical mechanisms. Hepatotoxicity is an indirect effect, resulting from the downstream metabolic processing of a metabolite (acetylhydrazine) by the CYP2E1 enzyme system.[1] In contrast, neurotoxicity is a direct effect of the parent drug molecule, which structurally interferes with the function of a vital coenzyme, pyridoxal phosphate.[1] This mechanistic distinction has critical implications for clinical management. While both are serious risks, neurotoxicity is a predictable, dose-related side effect that can be effectively prevented and managed with a simple, inexpensive intervention: pyridoxine supplementation.[4] Hepatotoxicity, on the other hand, is a more idiosyncratic and unpredictable reaction whose primary management involves vigilant monitoring and immediate drug cessation upon detection.[44] This nuanced understanding is essential for effective patient counseling, risk stratification, and safe prescribing.

C. Other Adverse Reactions

Beyond the primary organ toxicities, isoniazid can cause a variety of other adverse effects.

• Gastrointestinal: Nausea, vomiting, epigastric distress, and loss of appetite are common, particularly at the beginning of therapy.[30]
• Allergic and Dermatologic: Hypersensitivity reactions can manifest as maculopapular skin rashes, itching (pruritus), and fever.[1] In rare cases, severe and life-threatening reactions can occur, including drug-induced lupus erythematosus (DILE), Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN).[30]
• Hematologic: A reduction in blood cell production can occur, including agranulocytosis, eosinophilia, thrombocytopenia, and hemolytic or sideroblastic anemia.[2]
• Endocrine and Metabolic: Isoniazid has been associated with gynecomastia (breast enlargement in males) and hyperglycemia, requiring caution in diabetic patients.[49]

Contraindications and Clinically Significant Interactions

Safe administration of isoniazid requires a thorough assessment of patient-specific contraindications and a comprehensive review of potential interactions with other drugs, foods, and nutrients.

A. Absolute and Relative Contraindications

The use of isoniazid is prohibited or requires significant caution in certain clinical situations.

• Absolute Contraindications:
• Previous Isoniazid-Induced Hepatic Injury: Patients with a documented history of severe liver damage from a prior course of isoniazid should not be re-challenged with the drug.[44]
• Acute Liver Disease: Isoniazid is contraindicated in patients with active, acute liver disease of any etiology (e.g., acute viral hepatitis).[44]
• Severe Hypersensitivity: A history of a severe hypersensitivity reaction to isoniazid, such as drug fever, chills, or drug-induced lupus, is an absolute contraindication.[53]
• Relative Contraindications (Use with Caution):
• Chronic Liver Disease: Patients with stable chronic liver disease (e.g., cirrhosis) may receive isoniazid but require heightened vigilance and more frequent monitoring of liver function.[44]
• High-Risk for Toxicity: Caution is warranted in patients with multiple risk factors for toxicity, including daily alcohol consumption, severe renal dysfunction (especially in slow acetylators), pre-existing peripheral neuropathy, uncontrolled seizure disorders, diabetes, and malnutrition.[44]

B. Drug-Drug Interactions

Isoniazid is a known inhibitor of several cytochrome P450 enzymes, particularly CYP2E1, CYP2C19, and CYP3A4, leading to a large number of clinically significant drug-drug interactions.[2] It can increase the plasma concentrations and potential toxicity of many co-administered drugs. Table 3 summarizes some of the most critical interactions.

Table 3: Clinically Significant Drug-Drug Interactions with Isoniazid

Interacting Drug/Class	Potential Effect	Mechanism	Clinical Recommendation/Management	Source(s)
Acetaminophen (Paracetamol)	Increased risk of severe hepatotoxicity.	INH is a potent inducer of CYP2E1, the enzyme that converts acetaminophen to its toxic metabolite, NAPQI. INH also depletes glutathione stores needed for detoxification.	Concurrent use should be avoided. Counsel patients to use alternative analgesics (e.g., NSAIDs) if appropriate.	5
Anticonvulsants (e.g., Phenytoin, Carbamazepine, Diazepam)	Increased serum concentrations and risk of toxicity (e.g., ataxia, nystagmus, sedation).	INH inhibits the metabolism of these drugs (via CYP2C9, CYP2C19, CYP3A4). Slow acetylators are at higher risk.	Monitor serum drug levels of the anticonvulsant closely. Dose reduction of the anticonvulsant may be necessary.	5
Rifampin	Additive or synergistic risk of hepatotoxicity.	Both drugs are independently hepatotoxic. Rifampin is a potent inducer of CYP enzymes, which may increase the formation of toxic INH metabolites.	This combination is standard for TB treatment but requires vigilant monitoring of LFTs. Educate patient on symptoms of hepatitis.	7
Aluminum-Containing Antacids	Decreased gastrointestinal absorption of isoniazid.	Antacids can chelate or adsorb isoniazid, reducing its bioavailability.	Separate administration times by at least 1-2 hours.	14
Theophylline	Increased theophylline plasma levels and risk of toxicity (e.g., tachycardia, seizures).	INH inhibits the metabolism of theophylline.	Monitor theophylline levels and adjust dose as needed.	58
Warfarin	Increased anticoagulant effect and risk of bleeding.	INH may inhibit the metabolism of warfarin.	Monitor INR/prothrombin time frequently, especially upon initiation or discontinuation of INH. Adjust warfarin dose accordingly.	58
Certain CYP3A4 Substrates (e.g., Lovastatin, Lurasidone, Naloxegol)	Significantly increased plasma levels of the substrate, leading to toxicity.	INH is a moderate inhibitor of CYP3A4.	Co-administration with several sensitive CYP3A4 substrates is contraindicated due to high risk of severe adverse events (e.g., myopathy with statins, hypotension with flibanserin).	47

C. Drug-Food and Drug-Nutrient Interactions

Patient counseling should include guidance on interactions with alcohol, food, and specific nutrients.

• Alcohol: The concurrent use of alcohol and isoniazid significantly increases the risk of hepatotoxicity. Patients must be strongly advised to strictly limit or, ideally, avoid all alcoholic beverages during the entire course of treatment.[14]
• Food: As previously noted, food can decrease the absorption of isoniazid. To maximize bioavailability, it should be taken on an empty stomach.[40]
• Tyramine- and Histamine-Rich Foods: Isoniazid exhibits weak, non-selective monoamine oxidase inhibitor (MAOI) and stronger diamine oxidase inhibitor properties.[2] Consequently, the ingestion of foods rich in tyramine (e.g., aged cheeses, cured meats, fermented products, red wine) or histamine (e.g., certain fish like tuna, skipjack, mackerel) can precipitate a reaction. This may manifest as headache, sweating, flushing, palpitations, dizziness, or a hypertensive crisis.[14] Patients should be advised to avoid these foods.
• Vitamin Interactions:
• Vitamin B6 (Pyridoxine): Isoniazid directly antagonizes vitamin B6, leading to a functional deficiency and risk of peripheral neuropathy. Prophylactic supplementation is a standard part of care.[4]
• Vitamin B3 (Niacin) and Vitamin D: Evidence suggests that isoniazid may interfere with the metabolism of niacin and vitamin D. While the clinical significance is less clear than with vitamin B6, supplementation at standard daily intake levels may be beneficial, particularly in malnourished patients.[14]

The Challenge of Isoniazid Resistance

The single greatest threat to the continued utility of isoniazid and to the success of global tuberculosis control programs is the emergence and spread of drug resistance.

A. Genetic and Molecular Basis of Resistance

Resistance to isoniazid in M. tuberculosis is not acquired via horizontal gene transfer but arises from spontaneous chromosomal mutations that alter the drug's mechanism of action.[9] The primary mechanisms are well-characterized:

• Primary Mechanism: katG Gene Mutation: The most frequent cause of isoniazid resistance, accounting for 50-80% of resistant clinical isolates, is mutation within the katG gene.[2] This gene encodes the catalase-peroxidase enzyme required to activate the isoniazid prodrug. Mutations, most commonly the Ser315Thr substitution, result in an enzyme with reduced or no ability to convert isoniazid into its active form. This failure of activation prevents the drug from ever reaching its target and typically confers a high level of clinical resistance.[4]
• Secondary Mechanism: inhA Gene Mutation: The second most common mechanism involves mutations in the promoter region of the inhA gene (the structural gene for the enoyl-ACP reductase, isoniazid's primary target).[2] These mutations do not alter the target protein itself but lead to its overexpression. The increased quantity of the InhA enzyme in the cell effectively titrates out the inhibitory INH-NAD adduct, allowing mycolic acid synthesis to proceed. This mechanism usually confers a lower level of isoniazid resistance and is often associated with cross-resistance to the structurally related drug ethionamide.[4]
• Other Genes: Less frequently, mutations in other genes, such as ahpC (involved in peroxide stress response) and kasA (another enzyme in the mycolic acid pathway), have also been implicated in isoniazid resistance.[2]

B. Clinical Impact and Epidemiology

Isoniazid resistance is now the most common form of antitubercular drug resistance observed worldwide.[9] Its clinical impact is severe. The presence of isoniazid monoresistance (resistance to INH but susceptibility to rifampin) is associated with a significantly higher risk of treatment failure, relapse, and death compared to fully drug-susceptible TB.[9] Critically, inadequate treatment of isoniazid-resistant TB is a major driver for the acquisition of further drug resistance, particularly to rifampin. The emergence of resistance to both isoniazid and rifampin defines multidrug-resistant TB (MDR-TB), a far more dangerous and difficult-to-treat form of the disease that requires prolonged, toxic, and expensive second-line drug regimens.[9]

C. Clinical Strategies for Isoniazid-Resistant Tuberculosis

The management of TB in the presence of isoniazid resistance requires abandoning standard first-line therapy and employing alternative, evidence-based regimens. Rapid molecular diagnostics that can detect resistance mutations are crucial for guiding these decisions promptly.

• Isoniazid-Monoresistant TB (Hr-TB): For patients with TB resistant only to isoniazid, the World Health Organization (WHO) and other bodies recommend treatment with a 6-month, rifampin-based regimen. A commonly recommended regimen consists of rifampin, ethambutol, pyrazinamide, and a fluoroquinolone such as levofloxacin (abbreviated as 6 RZE-Lfx).[9] It is of paramount importance to confirm susceptibility to rifampin before initiating such a regimen to avoid inadvertently treating MDR-TB with functional monotherapy, which would amplify resistance.[9]
• Multidrug-Resistant TB (MDR-TB): As isoniazid is ineffective by definition, treatment relies on second-line and newer antitubercular agents. Historically, these regimens were 18-24 months long and involved injectable agents with severe toxicities.
• Recent Advances for Drug-Resistant TB: The therapeutic landscape for drug-resistant TB has been revolutionized in recent years by clinical trials demonstrating the efficacy of shorter, all-oral regimens built around new drugs like bedaquiline and pretomanid. Current international guidelines now recommend these regimens for rifampin-resistant TB (which encompasses most MDR-TB cases). The specific regimen depends on the strain's susceptibility to fluoroquinolones. These advances are summarized in Table 4.

Table 4: Recommended Treatment Regimens for Isoniazid-Resistant Tuberculosis

Resistance Pattern	Recommended Regimen	Duration	Key Drugs	Source/Guideline
Isoniazid-Monoresistant TB (Hr-TB)	Fluoroquinolone-containing regimen	6 months	Rifampin + Ethambutol + Pyrazinamide + Levofloxacin	WHO 2019; 9
Rifampin-Resistant / MDR-TB (Fluoroquinolone-Susceptible)	BPaLM Regimen	6 months	Bedaquiline + Pretomanid + Linezolid + Moxifloxacin	ATS/CDC/ERS/IDSA 2024; 10
Rifampin-Resistant / MDR-TB (Fluoroquinolone-Resistant)	BPaL Regimen	6 months	Bedaquiline + Pretomanid + Linezolid	ATS/CDC/ERS/IDSA 2024; 10

Synthesis and Expert Recommendations

Isoniazid is a landmark drug in the history of medicine, one whose discovery transformed the prognosis of tuberculosis and saved countless lives. Its story offers invaluable lessons on the entire lifecycle of an antimicrobial agent—from serendipitous discovery and rational development to the eventual challenges of toxicity and resistance. Despite these challenges, isoniazid remains a vital, effective, and affordable tool for the treatment of drug-susceptible TB and will continue to be a cornerstone of therapy in many parts of the world for the foreseeable future.

The following recommendations are derived from the comprehensive analysis presented in this monograph:

1. Embrace Personalized Medicine through Pharmacogenetics: The profound and predictable impact of NAT2 genetic polymorphism on isoniazid's pharmacokinetics, safety, and efficacy makes a compelling scientific and clinical case for the wider implementation of pharmacogenetic testing. Moving beyond the current "one-size-fits-all" dosing paradigm towards genotype-guided dose adjustments has the potential to significantly optimize therapy. A reduced dose for slow acetylators could substantially lower the risk of hepatotoxicity and neuropathy, while a moderately increased dose for fast acetylators could ensure adequate drug exposure, potentially improving cure rates and reducing the risk of acquired resistance. Prospective clinical trials are urgently needed to validate and standardize these personalized dosing strategies.
2. Reinforce Vigilance in Clinical Practice: The known risks of isoniazid necessitate unwavering clinical vigilance. Clinicians must prioritize patient education, ensuring that individuals understand and can recognize the early warning signs of hepatotoxicity and neuropathy. Counseling on the critical importance of alcohol avoidance and adherence to pyridoxine supplementation is non-negotiable for safe use. Furthermore, given the drug's role as a CYP450 inhibitor, a meticulous medication reconciliation is essential at the start of therapy and throughout treatment to identify and manage potentially harmful drug-drug interactions.
3. Advance the Fight Against Resistance: The future of tuberculosis control is inextricably linked to overcoming drug resistance. While isoniazid is a casualty in the treatment of MDR-TB, the principles learned from its 70-year history—the absolute necessity of combination therapy, the molecular mechanisms of resistance, and the critical role of patient adherence—have directly informed the development of the next generation of antitubercular regimens. The focus must remain on the continued research, development, and global deployment of shorter, safer, and more effective all-oral regimens, such as BPaL and BPaLM. Sustained investment in novel drug discovery, along with the development and accessibility of rapid molecular diagnostics to guide therapy, is essential to finally bring the global tuberculosis pandemic under control.

Works cited

1. Isoniazid: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 2, 2025, https://go.drugbank.com/drugs/DB00951
2. Isoniazid - Wikipedia, accessed August 2, 2025, https://en.wikipedia.org/wiki/Isoniazid
3. Isoniazid - Basicmedical Key, accessed August 2, 2025, https://basicmedicalkey.com/isoniazid/
4. What is the mechanism of action (Moa) of Isoniazid (Isonicotinic Hydrazide)? - Dr.Oracle AI, accessed August 2, 2025, https://www.droracle.ai/articles/135511/what-is-the-moa-of-isoniazid-
5. Isoniazid - StatPearls - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557617/
6. Should We Use N-Acetyltransferase Type 2 Genotyping To ..., accessed August 2, 2025, https://journals.asm.org/doi/10.1128/aac.49.5.1733-1738.2005
7. Isoniazid Toxicity - StatPearls - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK531488/
8. A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5038291/
9. Treatment of Isoniazid-Resistant Pulmonary Tuberculosis - PMC, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953491/
10. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline, accessed August 2, 2025, https://www.idsociety.org/practice-guideline/treatment-of-drug-susceptible-tb/treatment-of-drug-resistant-and-drug-susceptible-tb-2025-update/
11. Isoniazid | 54-85-3 - ChemicalBook, accessed August 2, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5102053.htm
12. Isoniazid | CAS 54-85-3 | SCBT - Santa Cruz Biotechnology, accessed August 2, 2025, https://www.scbt.com/p/isoniazid-54-85-3
13. CAS Number 54-85-3 | Isoniazid - Spectrum Chemical, accessed August 2, 2025, https://www.spectrumchemical.com/cas/54-85-3
14. Isoniazid (drug interactions) | EBSCO Research Starters, accessed August 2, 2025, https://www.ebsco.com/research-starters/health-and-medicine/isoniazid-drug-interactions
15. Isoniazid | C6H7N3O | CID 3767 - PubChem, accessed August 2, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Isoniazid
16. Isoniazid (PIM 288) - Inchem.org, accessed August 2, 2025, https://www.inchem.org/documents/pims/pharm/pim288.htm
17. “A Review Article An Isoniazid” - IOSR Journal, accessed August 2, 2025, https://www.iosrjournals.org/iosr-jpbs/papers/Vol19-issue6/Ser-2/B1906020813.pdf
18. The Mechanism of Isoniazid Killing: Clarity Through the Scope of Genetics, accessed August 2, 2025, http://farma.facmed.unam.mx/prac/PRAC%20TUBERCULOSIS/V1/29.5%20realimentacion%20-%20Vilcheze%20C,%20Jacobs%20WR%20Jr.%20The%20mechanism%20of%20isoniazid%20killing%20clarity%20through%20the%20scope%20of%20genetics.%20Annu%20Rev%20Microbiol.%202007%3B6135-50..pdf
19. Treatment of Tuberculosis. A Historical Perspective | Annals of the American Thoracic Society - ATS Journals, accessed August 2, 2025, https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201509-632PS
20. Isoniazid | Tuberculosis, Antibiotic, Treatment | Britannica, accessed August 2, 2025, https://www.britannica.com/science/isoniazid
21. Treatment of Tuberculosis. A Historical Perspective - ATS Journals, accessed August 2, 2025, https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.201509-632PS
22. History of Tuberculosis - Global TB Center - Rutgers University, accessed August 2, 2025, https://globaltb.njms.rutgers.edu/abouttb/historyoftb.php
23. Chemical & Engineering News: Top Pharmaceuticals: Isoniazid, accessed August 2, 2025, https://pubsapp.acs.org/cen/coverstory/83/8325/8325isoniazid.html
24. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4526730/
25. Tuberculosis Drug Discovery: Navigating Resistance and Developing New Therapies, accessed August 2, 2025, https://www.lshtm.ac.uk/research/centres/amr/news/427076/tuberculosis-drug-discovery-navigating-resistance-and-developing-new-therapies
26. Treatment of Tuberculosis. A Historical Perspective - PubMed, accessed August 2, 2025, https://pubmed.ncbi.nlm.nih.gov/26653188/
27. History of drug discovery: Early evaluation studies and lessons learnt from them, accessed August 2, 2025, https://pure.johnshopkins.edu/en/publications/history-of-drug-discovery-early-evaluation-studies-and-lessons-le-4
28. Isoniazid for treating tuberculosis - Lasker Foundation, accessed August 2, 2025, https://laskerfoundation.org/winners/isoniazid-for-treating-tuberculosis/
29. Isoniazid-historical development, metabolism associated ... - Frontiers, accessed August 2, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1441147/full
30. What are the side effects of Isoniazid? - Patsnap Synapse, accessed August 2, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-isoniazid
31. Recent advancements in tuberculosis (TB) treatment regimens - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11922356/
32. Isoniazid, Mechanism of Action, Biological Activity, Resistance and Biotransformation, accessed August 2, 2025, https://journals.ekb.eg/article_298591_c4520454940e7927bc6942eca141f72a.pdf
33. Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6965675/
34. (PDF) Isoniazid: An Exploratory Review - ResearchGate, accessed August 2, 2025, https://www.researchgate.net/publication/359764864_Isoniazid_An_Exploratory_Review
35. Isoniazid (Isonicotinylhydrazide, NSC 9659, CAS Number: 54-85-3) | Cayman Chemical, accessed August 2, 2025, https://www.caymanchem.com/product/20378/isoniazid
36. Effect of Isoniazid on the In Vivo Mycolic Acid Synthesis, Cell Growth, and Viability of
37. Mechanism of action of isoniazid | Request PDF - ResearchGate, accessed August 2, 2025, https://www.researchgate.net/publication/6722513_Mechanism_of_action_of_isoniazid
38. Mechanisms of action of isoniazid - WCM-Q SEARCH, accessed August 2, 2025, https://primo.qatar-weill.cornell.edu/discovery/fulldisplay?docid=cdi_proquest_miscellaneous_68180549&context=PC&vid=974WCMCIQ_INST:VU1&lang=en&search_scope=MyInst_and_CI&adaptor=Primo%20Central&tab=Everything&query=sub%2Cexact%2C%20Isoniazid%20-%20pharmacology%20%2CAND&mode=advanced&offset=40
39. Mechanism of Action of Isoniazid on Mycobacterium bovis Strain BCG - ASM Journals, accessed August 2, 2025, https://journals.asm.org/doi/10.1128/iai.3.4.530-534.1971
40. Isoniazid Pathway, Pharmacokinetics - PharmGKB, accessed August 2, 2025, https://www.pharmgkb.org/pathway/PA166151813
41. 8 Isoniazid Interactions to Watch Out For - GoodRx, accessed August 2, 2025, https://www.goodrx.com/isoniazid/interactions
42. Determination of the Isoniazid N-Acetylation Phenotype in a Sample Indian Population, accessed August 2, 2025, https://www.ijpsonline.com/articles/determination-of-the-isoniazid-nacetylation-phenotype-in-a-sample-indian-population.pdf
43. NAT2 Gene Polymorphisms and Plasma Isoniazid Concentration in Vietnamese Tuberculosis Patients, accessed August 2, 2025, https://wjst.wu.ac.th/index.php/wjst/article/download/6517/2065/52796
44. Isoniazid Disease Interactions - Drugs.com, accessed August 2, 2025, https://www.drugs.com/disease-interactions/isoniazid.html
45. ISONIAZID-INDUCED LIVER INJURY: PHARMACOGENETIC ASPECTS | Krasnova | Russian Journal for Personalized Medicine - Elpub, accessed August 2, 2025, https://persmed.elpub.ru/jour/article/view/56?locale=en_US
46. Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania | PLOS One - Research journals, accessed August 2, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141002
47. (isoniazid) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 2, 2025, https://reference.medscape.com/drug/isoniazid-342564
48. Latent Tuberculosis Infection Treatment Regimens - CDC, accessed August 2, 2025, https://www.cdc.gov/tb/media/pdfs/2024/07/Latent_TB_Infection_Treatment_Regimen_Table.pdf
49. 5 Isoniazid Side Effects You Should Know About - GoodRx, accessed August 2, 2025, https://www.goodrx.com/isoniazid/common-side-effects
50. Isoniazid and Alcohol/Food Interactions - Drugs.com, accessed August 2, 2025, https://www.drugs.com/food-interactions/isoniazid.html
51. Isoniazid Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 2, 2025, https://www.drugs.com/dosage/isoniazid.html
52. Recommended drug dosage - Guidelines on the Management of Latent Tuberculosis Infection - NCBI Bookshelf, accessed August 2, 2025, https://www.ncbi.nlm.nih.gov/books/NBK293811/
53. Isoniazid: MedlinePlus Drug Information, accessed August 2, 2025, https://medlineplus.gov/druginfo/meds/a682401.html
54. University of Groningen Pharmacogenetics of isoniazid-induced hepatotoxicity Perwitasari, Dyah Aryani; Atthobari, Jarir, accessed August 2, 2025, https://research.rug.nl/files/240466116/Pharmacogenetics_of_isoniazid_induced_hepatotoxicity.pdf
55. Isoniazid Toxicity - American Journal of Neuroradiology, accessed August 2, 2025, https://www.ajnr.org/ajnr-case-collections-diagnosis/isoniazid-toxicity
56. Rifampin and isoniazid (oral route) - Side effects & dosage - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/rifampin-and-isoniazid-oral-route/description/drg-20062747
57. Isoniazid (oral route, intramuscular route) - Side effects & dosage - Mayo Clinic, accessed August 2, 2025, https://www.mayoclinic.org/drugs-supplements/isoniazid-oral-route-intramuscular-route/description/drg-20064419
58. Isoniazid Interactions Checker - Drugs.com, accessed August 2, 2025, https://www.drugs.com/drug-interactions/isoniazid.html
59. Treatment of Isoniazid-Resistant Pulmonary Tuberculosis - PMC - PubMed Central, accessed August 2, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6953491/
60. Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018 - MDPI, accessed August 2, 2025, https://www.mdpi.com/1660-4601/18/6/2965
61. Updates on the Treatment of Drug-Susceptible and Drug-Resistant ..., accessed August 2, 2025, https://www.atsjournals.org/doi/10.1164/rccm.202410-2096ST